Project Grant R01CA285882
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$684K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), awarded a $540,288 Project Grant to the University of Florida to research the role of bacterial-derived small molecules in improving the efficacy of immunotherapy for non-small cell lung cancer (NSCLC). The project aims to characterize a bacterial metabolite called BAC429, which has been shown to augment the anti-tumor effects of anti-PD-1 immunotherapy in preclinical models. The research will...
The National Cancer Institute (NCI) awarded a $179,988 Project Grant under the Cancer Biology Research (CFDA 93.396) program to The Leland Stanford Junior University (Stanford University) for the project "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer." The goal is to identify bacterial functions that can enhance response to immune checkpoint blockade (ICB) cancer immunotherapy. The project will leverage metagenomic data analysis, genetic engineering of...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $127,629 to Harvard T.H. Chan School of Public Health to conduct research on the role of human leukocyte antigen (HLA) variations in immune response and the efficacy of immune checkpoint inhibitor (ICI) monotherapy for non-small cell lung cancer (NSCLC). The key objectives are to: 1) identify the mechanisms linking germline and somatic HLA variations, somatic mutations,...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) in the amount of $400,890 provides funding for research on microbiome-mediated modulation of immune checkpoint molecules in colorectal cancer. The research aims to profile patient-specific tumor-microbiome interactions and conduct molecular analyses to elucidate how the gut microbiome impacts immune checkpoint molecules in mismatch repair-proficient, microsatellite-stable colorectal tumors...
This $670,358 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to investigate the role of B cell lineages in mediating response to neoadjuvant immune-based therapy for resectable non-small cell lung cancer (NSCLC). The research will leverage unique clinical trial cohorts, human-relevant mouse models, and advanced multi-omics technologies to determine the transcriptional, immunogenomic, and spatial landscapes of B lineage cells in NSCLC...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $636,222 to the University of Pittsburgh to conduct research aimed at understanding how certain gut bacteria can modulate the immune system to enhance the efficacy of immune checkpoint inhibitor (ICI) cancer therapies, specifically in melanoma. The key objectives are to: Determine if ICI-associated bacteria can metabolize dietary tryptophan into aryl hydrocarbon receptor (AhR)...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $426,425 to Baylor College of Medicine to conduct a pilot study examining the relationship between gut microbiome composition, metabolic dysfunction-associated steatotic liver disease (MASLD), and hepatocellular carcinoma (HCC). The key objectives of this 2-year study are to: 1) characterize baseline gut microbiome diversity associated with MASLD with and without HCC, 2)...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $696,569 to New York University School of Medicine to conduct research aimed at developing novel therapies for lung cancer. The key objectives are to: 1) characterize the impact of the protein lipocalin 2 (LCN2) on the tumor microenvironment, 2) develop antibody-based therapeutics that interfere with LCN2 and assess their efficacy as monotherapy and in combination with immune checkpoint...
This $641,336 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Ohio State University aims to advance immunotherapy for non-small cell lung cancer (NSCLC). The project will investigate how disrupting the GARP-TGFbeta axis in the tumor microenvironment using the anti-GARP antibody PIIO-1 can enhance CD8+ T cell function and overcome resistance to immune checkpoint blockade therapy in NSCLC patients. Key objectives include defining how GARP...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...